Author | Vernon E. Steele, PhD, MPH


Strategies for Identification and Clinical Evaluation of Promising Chemopreventive Agents

October 01, 1996

ByGary J. Kelloff, MD|Ernest T. Hawk, MD, MPH|Charles W. Boone, MD, PhD|Susan G. Nayfield, MD, MSC|Marjorie Perloff, MD|Vernon E. Steele, PhD, MPH|Ronald A. Lubet, PhD|Caroline C. Sigman, PhD

Strategies for chemopreventative drug development are based on the use of well-characterized agents, intermediate biomarkers correlating to cancer incidence, and suitable cohorts for efficacy studies. Since